TherapeuticsMD Inc. (NASDAQ:TXMD) previous close was $1.05 while the outstanding shares total 347.22M. The firm has a beta of 1.93. TXMD’s shares traded higher over the last trading session, gaining 3.81% on 05/17/21. The shares fell to a low of $1.0482 before closing at $1.09. Intraday shares traded counted 6.19 million, which was 48.42% higher than its 30-day average trading volume of 12.01M. The stock’s Relative Strength Index (RSI) is 42.81, with weekly volatility at 5.34% and ATR at 0.07. The TXMD stock’s 52-week price range has touched low of $1.00 and a $2.75 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company TherapeuticsMD Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $432.68 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
TherapeuticsMD Inc. (TXMD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TXMD, the company has in raw cash 137.62 million on their books with 5.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. In terms of their assets, the company currently has 187.04 million total, with 61.28 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.17 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TXMD sounds very interesting.
Is the stock of TXMD attractive?
In related news, CAO and VP Finance, Donegan Michael C sold 4,842 shares of the company’s stock in a transaction that recorded on May 11. The sale was performed at an average price of 1.04, for a total value of 5,036. As the sale deal closes, the General Counsel, Walker Marlan D now sold 21,592 shares of the company’s stock, valued at 22,456. Also, EVP, Operations, BORKOWSKI EDWARD sold 44,252 shares of the company’s stock in a deal that was recorded on May 11. The shares were price at an average price of 1.04 per share, with a total market value of 46,022. Following this completion of acquisition, the Secretary/CEO of subsidiary, Milligan John C.K. IV now holds 44,252 shares of the company’s stock, valued at 46,022. In the last 6 months, insiders have changed their ownership in shares of company stock by 5.10%.